Given an appreciable risk of adverse-effects, chronic hepatitis C virus (HCV) patients face a dilemma regarding whether to accept or forego a course of therapy that can permanently clear their viral infection.
Emphasis was on patient-important outcomes; in particular: (1) Probability of viral-clearance conferring additional total life years, and (2) Probability of viral-clearance conferring additional life years spent in compensated health states (i.e. the avoidance of liver failure).
RESULTS:
The probability of benefiting from treatment-induced viral-clearance varied strikingly. It was lowest among patients at 60 years of age with initially mild fibrosis; 1.6% (95% CI: 0.8-2.7) and 2.9% (95% CI: 1.5-4.7) regarding outcome 1 and 2, respectively. It was highest among patients with compensated cirrhosis aged 30 years; 57.9% (95% CI: 46.0-69.0) and 67.1% (95% CI: 54.1-78.2) regarding outcome 1 and 2, respectively.
CONCLUSIONS:
For older patients with less advanced liver fibrosis, viral-clearance is less likely to confer benefit when measured in terms of averting liver failure and premature death. These data have important implications. Foremost, they will inform the contemporary patient quandary of immediate treatment with existing therapies (that have poor adverse-effect profiles) versus deferring until more tolerable (and more efficacious) regimens become available.
.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection leads to progressively worsening degrees of liver fibrosis (i.e. scarring of the liver). Eventually (over a period of many decades), fibrosis can become so extensive, that liver function is compromised. 1 Often, it is only at this point of hepatic decompensation that HCV infection becomes evident to the patient. Hereafter, in the absence of a liver transplant, long-term prognosis is bleak. 2 It is this typical sequence of events that has led to HCV being dubbed the "silent killer" [3] [4] .
Chronic HCV infection is treatable. Current treatments regimens (consisting of a 16-48 week course of pegylated interferon, ribavirin ± a protease inhibitor in genotype-1 patients) can permanently eradicate the infection in 67-75% of persons (based on the sustained viral response
[SVR] proxy). [5] [6] [7] The number of people treated every year is substantial; approximately 5,000-6,000, and 60,000-80,000 initiates each year in the UK and US, respectively. 8, 9 However current therapies are not a panacea; adverse-effects can be appreciable 10,11 and sometimes severe. [12] [13] [14] Moreover, patients failing first generation protease inhibitors can develop resistance to the class. 15 Accordingly, before embarking on a course of therapy, the patient (and their clinician) should carefully consider the risk-benefit ratio. Particularly given that, de-facto, the majority with infection are unlikely to develop overt liver disease, within the course of their lifetime 16, 17 So, to assist this patient-decision we simulated the lifetime course of liver disease according to SVR status and individualised patient factors. We envisage that these data, in conjunction with information regarding: (i)the probability of SVR, (ii)the adverse-effect profile, and (iii)the prospect that more tolerable and efficacious therapies will be available in the future 18 , will arm patients and clinicians alike, with a more complete picture when considering therapy with current (and future 18 ) treatment regimens.
MODEL PURPOSE:
To delineate the value of treatment-induced viral clearance, we created the Hepatitis-C Individualised Treatment-decision model (the HIT-model). The HIT-model simulates lifetime liver disease outcomes for individual model subjects, henceforth from two distinct scenarios: For each model subject, we then compared the course of liver disease under scenario-1 versus scenario-2.
MODEL OVERVIEW:
The HIT-model is a markov-chain model that simulates the lifetime course of HCV-related liver disease according to viral-clearance status. The model is run as a first order Monte-Carlo simulation, otherwise known as a microsimulation. 19, 20 The structure and parameterisation it assumes (see Fig-1 and Table-1) is typical of existing HCV simulation models (be they costeffectiveness 21-24 or burden forecasting models [25] [26] [27] ) and draws on a wide array of empirical research data.
As per the schematic in Fig.1 subjects with initial cirrhosis (Ishak-6) could progress to decompensated cirrhosis or HCC health states (and downstream states thereafter), but at a reduced rate relative to scenario-2 29 (see Table- 1). At every stage of the model (for both scenarios equally), subjects were susceptible to death from causes unrelated to HCV infection. Based on empirical data, we assumed these deaths occurred at an increased rate relative to the general population. 30-34 Finally, disease progression was simulated in annual cycles, until a maximum age of 90 years.
INDIVIDUALISED PATIENT FACTORS:
Outcomes were stratified according to individualised patient factors; these being initial fibrosis stage (Ishak 0-2, 3-5 and 6) and age (30, 45 and 60 years). Thus in total, disease course was simulated separately according to nine distinct patient types (i.e. all possible permutations of fibrosis stage and age).
PRIMARY OUTCOMES:
These reflected: patient-important events (those "perceptible to the patient and of sufficient value that changing their frequency would be of value to the patient" 35 ); the inceptive rationale for therapy (i.e. to prevent HCV-related complications and death 36 ); and the chief concerns of patients (premature-death and disease progression). 37 Hence as follows:
(i) OUTCOME-1: The likelihood of viral-clearance conferring additional years of life (ii) OUTCOME-2: The likelihood of viral-clearance conferring additional years of life in compensated health states (i.e. the avoidance of liver failure).
The rationale for outcome-2 is that in compensated disease states, the functioning of the liver is (by and large) unimpaired (i.e. by its very definition, the liver is able to compensate for the damage incurred). Accordingly, patient preferences for mild, moderate and compensated cirrhosis states do not differ. 38, 39 EXPRESSING OUTCOMES THROUGH PROBABILITY DISTRIBUTIONS:
Regarding outcome-1, we assembled the probability distribution for total life years gained (i.e. all 
EXPRESSING OUTCOMES THROUGH THE NUMBER-NEEDED-TO-SVR:
We determined the number needed to attain SVR in order to prevent one patient dying a premature HCV-related death (NNS 1 ); calculated as the reciprocal of the probability of gaining >0 additional life-years. Equally, we calculated the number needed to attain SVR in order to avert one patient from prematurely developing overt liver disease (NNS 2 ); calculated as the reciprocal of the probability of gaining >0 additional years in compensated health states.
The NNS is a HCV bespoke version of the number needed to treat (NNT). The NNT (referring to the number of patients that need to be treated in order to avert one additional adverse outcome) is well-regarded among clinicians as a meaningful measure of the effectiveness of a medical intervention. 40,41 Thus, the rationale for additionally framing the benefit of viral-clearance in an NNS format is to assist interpretation by clinicians and their patients (the target audience of this paper).
UNCERTAINTY DUE TO SAMPLING ERROR:
To quantify the overall uncertainty in our outcomes attributable to sampling error, we assigned probability distributions to model parameters (as specified in Table- 1), and sampled randomly from these. As is recommended for microsimulation models, 20 we adopted a stratified sampling approach (Latin hypercube) enabling a more efficient coverage of the sampling space than nonstratified sampling alone (thus permitting fewer replications and a less onerous computational intensity). For each set of random parameter draws (1000 performed in total) we ran each type of patient through the model 10,000 times (thus equating to 10 million simulations in total for each patient type). The variability (expressed as the 2.5 th and 97.5 th percentiles) of each outcome across these 1,000 parameter draws was used derive a 95% uncertainty interval.
SENSITIVITY ANALYSES:
We performed three one-way sensitivity analyses (SA) to assess the variability of our outcomes to pivotal parameters. As follows:
1. SA-1: We increased our base case fibrosis progression parameters, pro rata, to reflect 16% progression to cirrhosis at 20 years (as per alternative progression data on liver clinic attendees 42 ).
SA-2:
We decreased our base case fibrosis parameters, pro rata, to reflect 7% progression to cirrhosis at 20 years. The lower 7% progression rate 43 is appropriate when modelling the general infected population 44 (i.e. as for the US birth cohort screening intervention 45 ).
3. SA-3: we assumed no excess risk (compared to the general population) for non HCVrelated mortality.
RESULTS

OUTCOMES IN TERMS OF PROBABILITY DISTRIBUTIONS:
Gains in total life-years (outcome-1) and life-years spent in compensated disease states (outcome-2) attributable to viral-clearance, exhibited highly skewed distributions (see eFigure 1-2). For patients with initially mild or moderate fibrosis these probability distributions bespeak a situation where the majority gains minimally, but the minority gains considerably. Gains were more likely and more substantial for those treated at advanced fibrosis stages and younger ages. Patients with mild fibrosis at age 60 years of age had the lowest probability of benefiting from a SVR; a 1.6% (95%CI: 0.8-2.7) and 2.9% (95%CI: 1.5-4.7) chance in relation to outcome-1 and outcome-2, respectively (see Table- 
OUTCOMES IN TERMS OF NUMBER-NEEDED-TO-SVR:
The number needing to attain SVR in order to avert adverse outcomes was highly heterogeneous across individualised patient factors (Table-3 
DISCUSSION
Treating populations with chronic HCV is highly cost-effective 21-24 ; nevertheless, for the individual patient, there are clearly a range of benefits to be had. At its most extreme, the probability that a mildly fibrotic person at 60 years of age will benefit from viral-clearance (in terms of clinically apparent outcomes) is just 2-3%, whilst it is 58-67% for a cirrhotic person at 30 years of age (Table-2 ).This contrast is tantamount to a clinician needing to clear infection in, on average, ~35 times as many persons of the former description (versus persons of the latter) in order to avert the same number of HCV-related deaths ( Presently, SVR is labelled a "cure" 48 (language a patient would generally associate with an outcome that restores health). Analogously, pre-treatment discussions (between patient and clinician) weigh only the probability of SVR against the risk of adverse-effects. 47 In these ways, SVR can be portrayed as an outright benefit in itself. We caution that framing viral-clearance in this way (without consideration of age or disease-stage) may misguide patients apropos the value of therapy. At the same time, HCV initiatives are increasingly geared towards widening access to treatment. A simple utilitarian logic underpins this strategy: The more persons treated, the more cases of end-stage-liver-disease, in time, will be averted. Screening US baby boomers (persons born between 1945 and 1965) for HCV infection (with a view to treating those that screen positive) is a case-in-point. 45 This initiative will identify ~1.6 million patients with chronic infection, here-to-fore unaware of their condition. It is estimated that of these 1.6 million, more than 50% will be aged 45 years+ with mild fibrosis, or aged 60 yrs+ with moderate fibrosis 50 ; in other words, patient-groups that gain less from a SVR (assuming SVR is attained at all). Thus, on one hand, at the population level, birth-cohort screening will indeed avert a considerable number of end-stage liver disease cases over the years to come. All the same, from the perspective of any one individual patient, the likelihood of benefit may not always be sufficient to offset the adverseeffects of therapy. Ultimately, it is for the patient and their clinician (not the authors of this paper) to decide what is, and is not, an attractive risk-benefit ratio. However, it is for the medicalresearcher to arm them with an objective assimilation of the data. Accordingly, the data presented herein have important potential; particularly to inform the treatment decisions of individuals identified with chronic HCV infection via US birth cohort screening.
Hitherto HCV simulation models are pitched at policy makers; insofar as they focus on broad population-level outcomes, far-removed from the individual-level decision-to-treat 21-27 Our focus on addressing the questions that matter most to patients, in an intuitive way (in effect advocating a new patient-centred modelling approach), is the greatest strength of this paper. Various impediments hinder primary research studies, in their own right, from addressing these issues. In be considered. Thirdly, the HIT-model frames the benefit of SVR in terms of averting liver failure and premature death; sequelae that concern HCV patients most. 37 However, these outcomes may not capture the totality of HCV-induced adversities, and as such may understate the benefits of therapy. In particular: increased non-liver mortality is equivocal and not supported by many key studies. [56] [57] [58] [59] Ongoing scrutiny however, particularly with regard to vascular disease 60 , is required.
There are important implications to these data. In the short-term, this work will inform the contemporary patient dilemma of immediate treatment with existing therapies (that have poor adverse-effect profiles) versus awaiting interferon-free regimens that promise higher SVR rates with better tolerability. 17 Longer-term, it urges that broadened access to therapy be twinned with efforts to more objectively communicate (to the individual patient) the risk-benefit ratio of treatment. 
